Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPN60090 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
IPN60090 + paclitaxel is a combination therapy under clinical investigation for advanced solid tumors. IPN60090 (also known as IACS-6274) is a selective, orally bioavailable small molecule inhibitor of Glutaminase-1 (GLS1), an enzyme critical for cancer cell metabolism and proliferation through glutamine catabolism. Paclitaxel is a well-established chemotherapeutic agent that stabilizes microtubules and induces mitotic arrest and apoptosis in dividing cells. Combining IPN60090 with paclitaxel aims to target tumor metabolism and cell division simultaneously, potentially enhancing anti-tumor efficacy over monotherapy. Early-phase clinical trials are testing safety, pharmacokinetics, dose finding, and preliminary activity in patients with advanced cancers[1][3][4][6].
- Other names
- IACS-6274 + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))GAC (Group A carbohydrate antigen)ANPEP (Aminopeptidase N)
Beyond the preview
Go deeper on IPN60090 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPN60090 + paclitaxel.